文献速递类风湿关节炎

类风湿关节炎女性围孕期改善病情抗风湿药与生物制剂的启用与停用:队列研究

Perinatal use and discontinuation of disease-modifying anti-rheumatic drugs and biologics in women with rheumatoid arthritis: a cohort study.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该基于人群的队列研究纳入2002至2012年间分娩单胎的1301例RA女性共1730次妊娠,评估孕前24和12个月、各孕期及产后12个月六个窗口的RA药物使用与停用情况;结果显示妊娠早期药物停用比例较高,抗疟药57.3%、硫唑嘌呤59.1%、柳氮磺吡啶69.5%、生物制剂50.8%,提示需对计划妊娠的RA女性开展用药获益与风险教育。

要点

  • RA女性妊娠早期停用抗疟药、硫唑嘌呤、柳氮磺吡啶和生物制剂的比例分别为57.3%、59.1%、69.5%和50.8%。
  • 妊娠早期停用抗疟药与较低母亲年龄(OR 0.90,95%CI 0.86,0.95)及较多风湿科就诊次数(OR 0.86,95%CI 0.75,0.97)呈负相关。
  • 妊娠早期停用生物制剂与既往不良出生结局呈负相关(OR 0.22,95%CI 0.05,0.95)。

核心结论

  • 基于人群的研究显示RA女性围孕期药物停用频繁,尤其在妊娠早期。
  • 研究提示需对计划妊娠的RA女性开展妊娠期用药获益与风险教育。

研究设计与样本

  • 基于人群的行政数据队列研究,识别2002年1月1日至2012年12月31日间分娩单胎的RA女性。
  • 共纳入1301例RA女性的1730次妊娠,分娩时平均年龄31.4±5.4岁。
  • 评估孕前24和12个月、各孕期及产后12个月共六个窗口的RA药物使用与停用,停用定义为前一窗口有处方而当前窗口无处方。
  • 采用logistic回归模型评估预测因素,计算调整OR及95%CI。

主要发现

  • 妊娠早期停用抗疟药者占57.3%,停用硫唑嘌呤者占59.1%,停用柳氮磺吡啶者占69.5%,停用生物制剂者占50.8%。
  • 妊娠早期停用抗疟药与母亲年龄(OR 0.90,95%CI 0.86,0.95)及风湿科就诊次数(OR 0.86,95%CI 0.75,0.97)呈负相关。
  • 妊娠早期停用生物制剂与既往不良出生结局呈负相关(OR 0.22,95%CI 0.05,0.95)。

临床怎么用

  • 对计划妊娠的RA女性,应就妊娠期使用改善病情抗风湿药和生物制剂的获益与风险进行教育。
  • 围孕期应关注药物停用情况,尤其妊娠早期,并结合母亲年龄、风湿科就诊频率及既往不良出生结局等因素评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To characterize the utilization and discontinuation of medications before, during and after pregnancy among women with RA. METHODS: We used population-based administrative data to identify women with RA who had a singleton pregnancy ending in delivery between 1 January 2002 and 31 December 2012. We assessed the utilization of RA medications, namely, conventional synthetic DMARDs, biologics, glucocorticosteroids and NSAIDs, across six windows spanning 24 and 12 months before the start of pregnancy, each trimester of pregnancy and 12 months post-pregnancy. We defined medication discontinuation as no prescription in a given window following a prescription in the preceding window and evaluated predictors using logistic regression models, calculating adjusted odds ratios (ORs) and 95% CIs. RESULTS: We studied 1730 pregnancies in 1301 women with RA (mean age at delivery 31.4 ± 5.4 years). We observed substantial medication discontinuation, particularly in the first trimester, with discontinuation of antimalarials in 57.3% of patients, azathioprine 59.1%, sulfasalazine 69.5% and biologics 50.8%. Factors inversely associated with discontinuation of antimalarials in the first trimester were maternal age [OR 0.90 (95% CI 0.86, 0.95)] and number of rheumatology visits [OR 0.86 (95% CI 0.75, 0.97)] and for biologics, prior adverse birth outcome [OR 0.22 (95% CI 0.05, 0.95)]. CONCLUSION: Our population-based study shows frequent discontinuation of medications for RA, particularly in the first trimester. Findings indicate a need to educate women with RA who are planning pregnancy on the benefits and risks of medications during pregnancy.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Rebić N, Sayre EC, Zusman EZ, et al. Perinatal use and discontinuation of disease-modifying anti-rheumatic drugs and biologics in women with rheumatoid arthritis: a cohort study. Rheumatology (Oxford). 2020. PMID: 31628479. doi:10.1093/rheumatology/kez478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。